Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.
about
P1343
Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cellsGamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathwaysProstate cancer stem cellsClinical and experimental progression of a new model of human prostate cancer and therapeutic approachMembrane androgen binding sites are preferentially expressed in human prostate carcinoma cellsUnderstanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practiceHormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancerAdaptive responses of androgen receptor signaling in castration-resistant prostate cancerAndrogen receptor and prostate cancer stem cells: biological mechanisms and clinical implicationsA comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancerEnhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitorsPharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancerVariability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68.Molecular genetics of prostate cancer: new prospects for old challengesAltered differentiation and proliferation of prostate epithelium in mice lacking the androgen receptor cofactor p44/WDR77NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer.Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts.Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer.Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalkCorrelation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivationMicrofluidic-based 18F-labeling of biomolecules for immuno-positron emission tomography.Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer.Tissue-selective therapy of cancer.Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer.Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival.The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells.In vitro and in vivo model systems used in prostate cancer research.The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptorEGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/AktLoss of the androgen receptor cofactor p44/WDR77 induces astrogliosis.Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells.Prediction of treatment efficacy for prostate cancer using a mathematical model.Mouse models for studying prostate cancer bone metastasis.P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer.Antilipolytic drug boosts glucose metabolism in prostate cancer.
P2860
Q21132994-A4907D35-C5FE-415C-9ED8-AB10E01ACC24Q24646599-8D299289-F878-4CF5-9375-4962B6B46EDBQ24654712-2453A548-139D-45DE-A87A-E2E7A361C9E0Q24685731-48F42FDB-3568-4848-8D4C-0697F6BDBABAQ24800710-D28A82AC-210C-4A2E-8DBF-B85FD4CD843DQ26748538-11C5D0AE-B039-4F54-A4A1-DC1898D61B7FQ26773634-FE862A40-5AB8-4426-9447-7F36BC29B239Q26795625-2DF88CF4-1777-4B9E-8F07-B5F2C01DF3A6Q26797063-A39F4D2D-94C0-4DCB-A3F0-52876623C311Q27000180-DE7A221F-98B1-4473-A516-5DA71D595244Q27824772-E6EEF2D9-AF7D-42EE-924B-D8C4D403FB89Q30504566-FB1C862C-B776-46D1-8159-14110185F668Q30523968-095C2A40-F97A-4E15-98E6-82A983E63EEAQ31081891-84F7349F-CCEF-4DE3-A06F-F08C38B3BBC2Q33597393-381CC32C-AEC5-41EA-8DAF-39D48F128DFFQ33650205-C31ECF3E-72C7-45FD-A318-91CE49D75F6EQ33658285-97F5D0E8-094E-4BD2-BBFB-B1DCBB2974A4Q33772011-36B6917E-2361-465D-8A87-2D30C4B9FCF4Q34127462-3BAA2B58-3446-496F-AD38-ACC897CF8682Q34132534-E8AEA8A1-CF8F-4AA7-BB14-F5EFE95C5AC8Q34277988-DC3F9F20-ADE4-48E7-8D87-A6EF1465695EQ34482756-B9F3FEBB-4503-49D8-8204-A4CA3DEB45DFQ34717742-D290A0FA-AA61-4CFD-8BC8-5BAA29428A24Q35092971-0D7055F2-C816-4667-998E-F9A0CB4B6B22Q35111968-BD5F8A4D-2811-4DBE-BE74-EF788D240EB1Q35186923-65B20AEB-0138-4E7F-A721-189BE452092CQ35342962-5A8528DA-609B-4846-AEF4-BFC231479D2DQ35547765-D6CE77C9-0859-46C1-B1EF-4498DEAFEEB3Q35598954-A47A71F1-EE5F-43C3-8D7C-9AF1E22AF116Q35665662-869ED5FB-7482-4446-8D55-99971CC11925Q35758327-B4FE30EF-806D-47ED-874F-9AF28DF48FCDQ35806390-04F726B7-F1F9-403B-8E80-0610D1AF842FQ35838409-8B35B733-4D67-464F-A9A2-B6A12C588D07Q35945055-94FA55D9-3D3A-4AC1-B2C6-A55C1F56CE37Q36172838-1F6AE18F-0F29-41ED-AFD0-66FCE08F44A1Q36414352-BBF21DBA-9A64-4276-8789-88B47344D584Q36574383-5B027B9F-91B0-4093-9A67-F4EEED1F823BQ36590497-717A8C23-D12F-4305-B576-5809FEDBB630Q36687323-35FBF268-6DB5-4356-A9E5-7F023CBF979FQ36871763-1426097D-8307-4F98-9E45-2D53AB7AAC13
P2860
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Evidence for clonal outgrowth ...... rs through a two-step process.
@en
type
label
Evidence for clonal outgrowth ...... rs through a two-step process.
@en
prefLabel
Evidence for clonal outgrowth ...... rs through a two-step process.
@en
P2093
P1433
P1476
Evidence for clonal outgrowth ...... rs through a two-step process.
@en
P2093
Belldegrun A
DeKernion J
Sawyers CL
P304
P407
P4510
P577
1999-10-01T00:00:00Z